在与肥胖有关的心力衰竭中,心房动和塞马格卢提德的作用与保存的喷射小部分:STEP-HFpEF程序
Subodh Verma1, Javed Butler2, Barry A Borlaug3
1Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada.
Journal of the American College of Cardiology
|September 1, 2024
概括
塞马格卢提德显著改善了与肥胖相关的心力衰竭患者的心力衰竭症状和身体限制,并保留了喷射分数 (HFpEF),在心房动 (AF) 患者中观察到更大的好处. 该药物还降低了体重和关键生物标志物.
科学领域:
- 心脏病学 心脏病学
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 肥胖是心脏衰竭的重要危险因素,其中包括心脏衰竭与保存的喷射分数 (HFpEF) 和心房动 (AF).
- 该STEP-HFpEF计划证明了塞马格卢提德在改善肥胖患者的HFpEF症状和减轻体重方面的有效性.
- 塞马格卢提德对不同AF状态的HFpEF患者的影响需要进一步调查.
研究的目的:
- 描述HFpEF患者与没有AF病史之间的基线差异.
- 评估SEMAGLUTIDE在STEP-HFpEF计划中的有效性是否受到AF的存在或类型的影响.
主要方法:
- 来自STEP-HFpEF和STEP-HFpEFDM试验的汇总数据的二次分析.
- 1145名患有与肥胖相关的HFpEF的患者在52周内接受了2.4毫克或安慰剂.
- 根据KCCQ-CSS,体重,6分钟步行距离,复合终点,CRP和NT-proBNP的变化,根据AF史分层评估有效性.
主要成果:
- 45%的参与者有AF的病史,随着年龄的增长,NT-proBNP的增加,以及更先进的HF症状.
- 与没有AF的患者相比,塞马格卢提德在KCCQ-CSS和等级组合终点中表现出显著更大的改善.
- 在所有亚组中,无论AF状态如何,塞马格卢提德始终降低了体重,CRP和NT-proBNP.
结论:
- 心房动在与肥胖相关的HFpEF中很常见,并且与更严重的疾病特征有关.
- 在患有或没有AF的患者中,塞马格卢提德对HFpEF症状,身体功能和生物标志物具有显著的益处.
- 对于HF症状和局限性,塞马格卢提德的治疗益处在有AF病史的患者中更为明显.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
01:23Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
01:26Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352